UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJY) gapped down before the market opened on Monday . The stock had previously closed at $142.74, but opened at $134.70. UCB shares last traded at $134.58, with a volume of 784 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on UCBJY shares. Jefferies Financial Group raised shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Zacks Research upgraded shares of UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

UCB Stock Down 1.0%

The firm has a 50 day moving average of $144.02 and a two-hundred day moving average of $148.05. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.